Phase I Trial of DAR-901

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center Identifier:
First received: February 13, 2014
Last updated: August 7, 2015
Last verified: August 2015
This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV negative and HIV positive adults previously vaccinated with BCG. The goals of the trial are to determine the safety, tolerability, and immunogenicity of multiple doses of the vaccine at different dose levels, ranging from 0.1 to 1 mg.

Condition Intervention Phase
Biological: DAR-901
Biological: BCG
Biological: Sterile saline
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG

Resource links provided by NLM:

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Safety [ Time Frame: 10 months ] [ Designated as safety issue: Yes ]
    Subjects will be followed for both systemic side effects and injection site reactions

Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: 10 months ] [ Designated as safety issue: No ]
    Cellular and humoral responses to the vaccine antigen will be tested at baseline and after each of 3 doses of vaccine

Estimated Enrollment: 77
Study Start Date: February 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DAR-901

Intradermal administration at 0, 2 and 4 months

Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL

Biological: DAR-901
Other Name: Inactivated Mycobacterium obuense
Active Comparator: BCG
Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
Biological: BCG
Placebo Comparator: Sterile saline
Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
Biological: Sterile saline


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

All subjects: age 18-65, prior BCG vaccine (scar)

56 HIV negative subjects: negative ELISA for HIV (48 subjects with negative IGRA, 8 subjects with positive IGRA)

21 HIV positive subjects: positive ELISA for HIV, on ART (13 subjects with negative IGRA, 8 subjects with positive IGRA)

Exclusion Criteria: pregnancy, positive serology for hepatitis B or C, active tuberculosis immunosuppression, severe medical illness

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02063555

United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Charles F. von Reyn, MD Geisel School of Medicine at Dartmouth
  More Information

No publications provided

Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT02063555     History of Changes
Other Study ID Numbers: DAR-901-MDES
Study First Received: February 13, 2014
Last Updated: August 7, 2015
Health Authority: United States: Food and Drug Administration
United States: Dartmouth Committee for the Protection of Human Subjects

Keywords provided by Dartmouth-Hitchcock Medical Center:
TB Vaccines

Additional relevant MeSH terms:
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections processed this record on November 30, 2015